null

null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal long-term debt; small-cap clinical-stage biotech with equity-financed operations; a 20bp rate rise adds negligible interest burden.

Low sensitivity; MetaVia carries minimal variable-rate debt, so a 20bp rate increase has immaterial direct P&L impact; indirect equity cost-of-capital effect is moderate.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API/reagent sourcing from U.S.-China trade corridor and European CRO networks; Taiwan semiconductor content in lab instrumentation is secondary chokepoint.

Primarily U.S.-domiciled; limited international revenue exposure; sovereign currency devaluation risk is negligible at current stage.

Operations concentrated in U.S. (San Diego HQ); no material revenue from high-devaluation-risk currencies; FX exposure is minimal.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single CRO/CMO partners for clinical manufacturing; substitution would require 6–18 months and regulatory re-filing, exceeding 30% operational input threshold.

Clinical-stage biopharmaceutical; revenue model is milestone/grant-based, not SaaS; cloud infrastructure termination would disrupt data systems but not core drug development pipeline.

Preclinical and clinical research operations rely on lab informatics and electronic data capture platforms; short-term disruption but data portability is feasible within 60–90 days.

Moderate API/platform coupling in clinical data systems (Medidata, Veeva); switching cost estimated at $500K–$2M and 3–6 months of re-validation effort.

Low Howey risk; revenue derived from drug development milestones and licensing; no token or investment-contract product; standard equity securities only.

Very High

Patient clinical trial data subject to HIPAA and EU Clinical Trial Regulation; GDPR exposure moderate if EU trial sites active; CCPA exposure low given B2B/clinical context.

Low antitrust risk; small-cap biotech with no dominant market position; pipeline assets in competitive therapeutic areas with multiple incumbents.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional/milestone-based; no recurring subscription revenue; licensing deals and grant income constitute near 100% of current revenue.

Drug licensing milestones, royalties on future commercialization, and non-dilutive grant funding; no SaaS or subscription vector present.

Pricing is externally benchmarked via licensing negotiation; no direct product pricing control until commercialization; milestone economics set by partnership terms.

Low near-term pricing power as licensor; dependent on partner negotiations; post-approval pricing power moderate if differentiated mechanism of action validated.

Pre-revenue clinical stage; target gross margin post-commercialization estimated 70–85% for licensed biologics/small molecules under royalty model.

No subscription base; free-rider risk not applicable; partnership churn risk is binary — loss of single licensing partner would be material given concentrated deal structure.

Headcount-linear at current stage; doubling pipeline throughput requires proportional CRO spend and internal scientific staff; sublinear scaling only achievable post-commercialization.

Marginal cost of advancing each additional clinical asset is high (~$5M–$50M per program); scaling is capital-intensive and largely non-automated at clinical stage.

Not applicable; MetaVia operates no franchise network.

No traditional CAC; partnership acquisition cost is high (years of R&D spend per deal); at 10x scale, BD infrastructure and regulatory headcount would need significant expansion.

No meaningful network effects; drug development value is asset-specific, not network-driven; platform data assets could create weak indirect network effects over time.

-116.6% Return on Assets (Negative equity)

Low recession resistance; clinical-stage biotech funding highly sensitive to risk-off capital markets; partnership deal flow compresses in recessions.

Large pharmaceutical and biotechnology licensing partners (Big Pharma business development units) are primary customer segment.

Government and non-profit grant agencies (NIH, BARDA) represent secondary funding segment, providing non-dilutive capital for early-stage programs.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocation skewed toward clinical pipeline advancement (future-state); minimal legacy infrastructure; R&D spend constitutes ~85–90% of total operating expenditure.

0001638287

MTVA